Deferoxamine addresses metabolic dysregulation and urinary tract infections in weight-associated gestational diabetes mellitus
DFO holds potential as a targeted treatment for GDM associated with obesity by addressing iron excess and immune-metabolic dysregulation. LAMA3 plays a crucial role in mediating DFO's anti-inflammatory and survival-promoting effects via the PI3K/AKT pathway. Further clinical studies are needed to explore DFO's therapeutic potential in GDM.
Authors
- Xiaojing Yang (ORCID: https://orcid.org/0000-0001-9802-0189)
- Min Zhang (ORCID: https://orcid.org/0000-0002-1345-0604)
- Yue Xu (ORCID: https://orcid.org/0000-0002-5516-7989)
- Rong Lin (ORCID: https://orcid.org/0009-0002-8075-2669)
- Qingfu Zhang (ORCID: https://orcid.org/0000-0002-9891-1296)
- Lina Jia (ORCID: https://orcid.org/0000-0002-0448-4909)
- Na Wei (ORCID: https://orcid.org/0000-0002-6273-6852)
Institutions
- Hebei Medical University (CN)
- Taian City Central Hospital (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s40001-025-03013-4
- Citations
- 1
- Primary Topic
- Gestational Diabetes Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.06